Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model

Pancreas

Volumn 33, Issue 2, 2006, Pages 142-147

  Tsujie, Masanori ^a   Nakamori, Shoji ^a,b,c   Nakahira, Shin ^a   Takeda, Setsuo ^a   Takahashi, Yuji ^a   Hayashi, Nobuyasu ^a   Okami, Jiro ^a   Nagano, Hiroaki ^a   Dono, Keizo ^a   Umeshita, Koji ^a   Sakon, Masato ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Surgery   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

5 fluorouracil; Combination chemotherapy; Gemcitabine; Human equilibrative nucleoside transporter; Pancreatic cancer; Uracil tegafur

Indexed keywords

EQUILIBRATIVENUCLEOSIDE TRANSPORTER1; GEMCITABINE; MESSENGER RNA; NUCLEOSIDE TRANSPORTER; RECOMBINANT DNA; TRITIUM; UFT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG UPTAKE; EVALUATION; FEMALE; GENE EXPRESSION; GENE INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; RNA, MESSENGER; TEGAFUR; URACIL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746790663     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000226882.48204.26     Document Type: Article

References (30)

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057.
2. HA Burris 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Kulke MH. Advanced pancreatic cancer: is there a role for combination therapy? Expert Rev Anticancer Ther. 2003;3:729-739.
4. El-Rayes BF, Philip PA. Systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 2002;2:426-436.
5. Huang P, Chubb S, Hertel LW, et al. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110-6117.
6. Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998;25:887-895.
7. Baldwin SA, Mackey JR, Cass CE, et al. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today. 1999;5:216-224.
8. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349-4357.
9. Pressacco J, Wiley JS, Jamieson GP, et al. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer. 1995;72:939-942.
10. Pressacco J, Mitrovski B, Erlichman C, et al. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res. 1995;55:1505-1508.
11. Rauchwerger DR, Firby PS, Hedley DW, et al. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60:6075-6079.
12. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt). 1999;13:17-21.
13. Hoff PM, Royce M, Medgyesy D, et al. Oral fluoropyrimidines. Semin Oncol. 1999;26:640-646.
14. Miyamoto A, Nagano H, Sakon M, et al. Clinical application of quantitative analysis for detection of hematogenous spread of hepatocellular carcinoma by real-time PCR. Int J Oncol. 2000;18:527-532.
15. Finke J, Fritzen R, Ternes P, et al. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques. 1993;14:448-453.
16. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′, 2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000-5008.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1993;65:55-63.
18. Fukushima M, Satake H, Uchida J, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693-698.
19. Braakhuis BJ, Ruiz van Haperen VW, Boven E, et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol. 1995;22(11 suppl):42-46.
20. Goldin A. Combined chemotherapy. Oncology. 1980;37(suppl 1):3-8.
21. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
22. Correale P, Cerretani D, Marsili S, et al. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer. 2003;39:1547-1551.
23. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′, 2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000-5008.
24. Ruiz van Haperen VW, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2′, 2′-difluorodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994;54:4138-4143.
25. Xu Z, Friess H, Solioz M, et al. Bcl-x (L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer. 2001;94:268-274.
26. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002;62:354-362.
27. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998;16:2877-2885.
28. Takechi T, Fujioka A, Matsushima E, et al. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2, 4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002;38:1271-1277.
29. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology. 1997;54 (1 suppl):12-18.
30. Choi DS, Handa M, Young H, et al. Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporter 1 (ENT1) gene. Biochem Biophys Res Commun. 2000;277:200-208.